At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Entrada is paring back its research staff even as it gears up to hire employees to support a planned clinical trial for a ...

It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in ...

Learn how to extract the full value from executive coaching, starting with being open and honest with your coach.

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...